Indeed, some studies have reported that prolonged treatment of obese and diabetic mice with thiazolidinediones (TZDs, selective PPARγ ligands and activators), including troglitazone, rosiglitazone, and pioglitazone, results in the development of severe hepatic steatosis [24]. Here, PPARG is linked to fatty liver disease.